Demographics and baseline characteristics
| Parameter . | Values . |
|---|---|
| Patients treated | 22 (100) |
| Male/female | 7/15 |
| Age, median (range), y | 64 (25-76) |
| KPS, median (range) | 90 (80-100) |
| HLA-A* 02:01 positive | 9 (40.9) |
| Primary de novo AML | 22 (100) |
| ELN risk stratification | |
| Favorable | 8 (36) |
| Intermediate | 10 (46) |
| Adverse | 3 (14) |
| Undetermined | 1 (4) |
| Prior therapy | |
| Induction: Ara-C and anthracycline | 21 (96) |
| 7+3 (D60) | 9 (41) |
| 7+3 (D90) | 8 (37) |
| 7+3(I) | 1 (4) |
| 5+3 (I) | 3 (14) |
| Postremission therapy | 21 (96) |
| 1-2 cycles | 9 (41) |
| HiDAC based | 4 (18) |
| IDAC based | 5 (23) |
| 2-4 cycles | 13 (59) |
| HiDAC based | 8 (36) |
| IDAC based | 5 (23) |
| Time to GPS from CR1, median (range), mo | 8 (2-22) |
| Parameter . | Values . |
|---|---|
| Patients treated | 22 (100) |
| Male/female | 7/15 |
| Age, median (range), y | 64 (25-76) |
| KPS, median (range) | 90 (80-100) |
| HLA-A* 02:01 positive | 9 (40.9) |
| Primary de novo AML | 22 (100) |
| ELN risk stratification | |
| Favorable | 8 (36) |
| Intermediate | 10 (46) |
| Adverse | 3 (14) |
| Undetermined | 1 (4) |
| Prior therapy | |
| Induction: Ara-C and anthracycline | 21 (96) |
| 7+3 (D60) | 9 (41) |
| 7+3 (D90) | 8 (37) |
| 7+3(I) | 1 (4) |
| 5+3 (I) | 3 (14) |
| Postremission therapy | 21 (96) |
| 1-2 cycles | 9 (41) |
| HiDAC based | 4 (18) |
| IDAC based | 5 (23) |
| 2-4 cycles | 13 (59) |
| HiDAC based | 8 (36) |
| IDAC based | 5 (23) |
| Time to GPS from CR1, median (range), mo | 8 (2-22) |
Values are n (%) unless otherwise noted.
7+3, cytarabine (200 mg/m2) × 7 days + anthracycline × 3 days; Ara-C, cytarabine; D60, daunorubicin 60 mg/m2; D90, daunorubicin 90 mg/m2; HiDAC, high-dose cytarabine 2000 to 3000 mg/m2 for 6 to 12 doses; I, idarubicin 12 mg/m2; IDAC, intermediate-dose cytarabine 1000 to 1500 mg/m2 for 6 to 12 doses; KPS, Karnofsky performance status.